UNITED STATES DISTRICT COURT

DISTRICT OF NEW JERSEY - TRENTON

MUTUAL PHARMACEUTICAL COMPANY, INC., et. al.,

Plaintiff, : DOCKET NO. CU-09-5421

vs. : TRENTON, NJ

WATSON PHARMACEUTICALS, : July 14, 2010

INC., et. al.,

:

Defendant.

TRANSCRIPT OF CONFERENCE CALL HEARD BEFORE HONORABLE TONIANNE J. BONGIOVANNI, U.S.M.J.

TRANSCRIPT ORDERED BY:

DAMIAN P. CONFORTI, ESQ.
Podvey, Meanor, Catennaciti, Hildner, Cocoziello & Chattman, PC
The Legal Center
One Riverfront Plaza, 8th Floor
Newark, New Jersey 07102

APPEARANCES:

(On next page)

AudioEdge Transcription, L.L.C. 425 Eagle Rock Avenue Roseland, New Jersey 07068 (973) 618-2310 www.audioedgetranscription.com

APPEARANCES:

GREG MILLER, ESQ. (Podvey, Meanor, Catennaciti, Hildner, Cocoziello & Chattman, PC)
NISHAN KOTTAHACHCHI, ESQ.
Attorneys for Plaintiff

DAVID NOVACK, ESQ. (Budd Larner) Attorney for defendant Excellium

JARED LINA, ESQ.
KAREN BRAGMAN, ESQ.
MICHAEL DORE ESQ.
CLARK SULLIVAN, ESQ.
Attorneys for defendant West-Ward

ROBERT SCHOENBERG, ESQ.
WYVAL MARCUS, ESQ.
CAMERON REABER, ESQ.
Attorneys for defendant Vision

THE COURT: Good morning. How are you, folks?

UNIDENTIFIED SPEAKER: Good morning.

UNIDENTIFIED SPEAKER: Good morning, Judge.

UNIDENTIFIED SPEAKER: Good morning, Your Honor.

THE COURT: And we're on the record to discuss the outstanding discovery issues that I have in the letters lined up for me beginning June 17th. Let me ask you if you had any conversation and if there's been any resolution of any of these issues or if I should just go through each of the interrogatories that were raised in the June 17th letter?

MR. NOVACK: Judge, this is David Novack from Budd Larner for Excellium. And we're, I guess, the target of that letter. We have not had a further discussion with our adversary. However, we continue to make progress on reviewing and producing documents. We have retained, or re-retained I should say, accompany to copy and review our electronic documents. We have more hard copy documents to produce and we're making progress.

THE COURT: Okay. What is the targeted date for when you'll be complete with your disclosures, do you know?

MR. NOVACK: I don't know. The -- there was a problem in copying -- originally in copying one of the hard drives due a power failure at the facility. That's being redone. And after they have that hard drive, we should have a better idea as to the scope of the project of reviewing the

documents to mark confidential, privileged and relevant documents. The hard copies that we have should be ready to produce by the beginning of next week.

THE COURT: Okay. All right. Anything from plaintiffs before we go through this?

MR. MILLER: Your Honor, this is Greg Miller. I'll let Nishan Kottahachchi take most of this. But the one question I have and issue I want to raise is, with respect to Excellium now indicating that it's going to be producing documents. It's still unclear to us whether those documents and other information are responsive to what they term to be non-objectionable requests or whether or not they've changed their position with respect to the issues laid out in our letters to you. So I think we need some clarification there to understand where everything --

THE COURT: Okay. Well, I think that's where I can help regardless of what Mr. Novack's client's position is. I did go through each of the items that is contained in -- are contained in the June 17th letter. And painting with a broad brush, it's clear from reading the complaint that the allegations here are all focused on the advertising, marketing and promotion of this product. So anything that is in any of the defendant's control that relates to the marketing of the product. And I think document request Number 38 just talks also about safety, ethicacy, substitutability and FDA approval

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

I mean, that's obviously what the plaintiff's main status. concern is. But any of that type of information that's in any documents that are within the defendant's control or generated by the defendant, whether it's labeling material, whether it's correspondence that discusses how to market this material, whether it's correspondence that talks about a relationship with anyone else in terms of advertising. For example, those other parties that are mentioned. I guess the wholesaler, ordering system folks, any of that type of information should be produced. So I would narrow, for example, document request Number 14 where it asks for communication with these wholesalers to simply -- any communications with wholesalers that relate to the marketing of the product. And, for example, if it talks about safety, ethicacy, the substitutability and the FDA approval status. That's, again, me painting with a broad brush.

Going through all of these, I would tell you that the only limitations I would really put on any of these would be, as I said, Number 14, that it just needs to be narrowed to talk about marketing. I don't see the -- I don't see the relevance of the information that you're seeking regarding medicaid and medicare unless, again, we're talking about in your communication with any of those government insurance programs if there is information in those communications that relates to the marketing of the product.

Stepping back to Number 27 for a minute. I guess to the extent that the corporate structure is an issue, it seems to me that in your responses -- in defendant's responses to Rule -- in your Rule 26 disclosures and in your responses you should be identifying anyone who is involved in the marketing advertising. So while that's listed as a document request, if it isn't covered in an interrogatory, I would suggest that you answer that specifically and that would alleviate your having to produce the whole corporate structure. And the only other question I really had was Number 17. Was there an agreement as to the time period?

UNIDENTIFIED SPEAKER: Judge, there's -- I think that there was. And there's some tension there because of what's really relevant in this case. You know, we're going back through -- we're not a big company, we're not computerized, we're going through hard copy documents. Frankly, we've come to a negotiation but we frankly just still don't understand what relevance any of our advertising had prior to the July 30, 2009 approval date. You know, maybe that's just my inability to understand the plaintiff's case.

MR. KOTTAHACHCHI: Your Honor, this is Nishan

Kottahachchi for the plaintiffs. As counsel for Excellium

noted, there was an agreement as a result of two confirmed

meetings that resulted in the July 29, 2006 time limitation.

The reason that date is relevant is that's three years before

the date of approval of plaintiff's product. We used three years of the date to go back because a lot of the information that was provided to the price list and wholesalers, it's our understanding, was done before that date. Before the FDA approval. And in order to find out what was said about these products, which eventually got onto the price list and wholesale ordering systems, we need to go back some date before 2006. We thought three years was reasonable. We initially went with five years date, but then -- five years before but then initially withdrew it to three years. We think that's a reasonable time limitation and is necessary to find out -- get the documents and the information that is at the heart of this litigation.

THE COURT: Well, Mr. Novack, I don't want to touch an agreement if you had one.

MR. NOVACK: Judge, I would concede that -- what Nishan said is accurate. And, you know, we're working on it.

THE COURT: Okay.

MR. NOVACK: We're basically doing a page by page review of the client's documents. Frankly searching for a needle in the haystack because while -- you know, from an objective point of view one would think that there was significant correspondence regarding this drug with these selling procedures. There isn't.

THE COURT: Well, I understand from your papers that

it sounded to me anyway that your client does not market in a way that you are, I guess, the stereotypical view of marketing. That you have these price lists and that you go to trade shows but with the price list and you're not doing an out and out advertisement campaign. That's what it sounded like to me from your papers.

MR. NOVACK: Judge, I don't want to be a witness in this case, but I have been involved in this industry for quite some time. And the way that people in my client's situation, basically the generic drug industry, they sell based on price only. They don't advertise, they don't promote their products as you suggested in the traditional marketing campaign. They don't do those -- they don't participate in those kinds of activities.

THE COURT: Is most of the material --

MR. NOVACK: We're not looking for, you know, an advertising campaign with our marketing agents or anything like that. Those documents don't exist.

THE COURT: Is most of the information that you're searching through, Mr. Novack, on a computer where you can do term searches?

MR. NOVACK: Well, that's -- that is the information. Some of it is, some of it is hard documents. The information that I indicated earlier that were getting copied off of the various hard drives at the company, that will be put into a

searchable format.

THE COURT: Okay.

MR. NOVACK: And so that we would expect to identify communications with the price list and wholesalers. And we'll be producing that.

THE COURT: Okay.

MR. NOVACK: Such as it is.

THE COURT: All right. So is there any question about where I'm going with all of these -- the issues that you've raised? Again, I know I have spoken by painting with a broad brush, but I think that what I've stated could be applied to each of these fairly easily with the caveats or clarifications or limitations that I mentioned as to those specific items. Does that work for everyone?

MR. NOVACK: I think it does work for us, Judge.

THE COURT: Okay.

MR. NOVACK: Novack again.

THE COURT: And what I'd like to do is, and I don't mean to torture you folks, but I'm trying to balance, keeping you moving, but also recognizing that there is some problem that the defendants are having in their document production.

So what I'd like to get, in particular from you, Mr. Novack, is an update as to where we are with the production of all of these items by mid-August. And then I can, perhaps in less of a vacuum, address the schedule issue that we have. I know we

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

have an end date in September for fact discovery. That there's been a request to extend that by 60 to 90 days. The plaintiffs somewhat reluctantly have agreed that they understand that perhaps a 60 day extension might be necessary. But I somewhat like to hold everyone's feet to the fire and get an update on documentation production the middle of next month. And then I can go from there and perhaps give an extension based on what I see or address any additional problems with the delay so that hopefully the next extension I give is the last. And you folks are certainly free to start scheduling depositions in September if you'd like knowing -- you know, September, October, November knowing that I will give you at least the 60 days that sounds reasonable. But I don't want to be in a position where we all put this on the back burner because we now have a little bit of breathing room. So again, coming full circle, if I can just get an update whether it's a joint letter, whether it's easier just for everyone to send me an individual letter saying this is where we are and we think, in light of where we are, that the 60 days would be ample time to wrap everything up. And if I can have that letter by August 20th, that would be great.

UNIDENTIFIED SPEAKER: Okay.

THE COURT: Okay? So we have an understanding that I will be giving you an extension in the discovery schedule, I'm just not entering it yet because I want to take your pulse on all of this and make sure that what we do next makes perfect

sense. And also if I have to get your attention before the summer's over then I can get you folks back on the phone and perhaps nudge someone not so gently. Good?

MS. BRAGMAN: Your Honor, Karen Bragman on behalf of defendant West-Ward. I have one question about the scheduling order.

THE COURT: Sure.

MS. BRAGMAN: That is, can we assume that all of the other dates --

THE COURT: Oh, yes.

MS. BRAGMAN: -- the critical dates in the scheduling order would be moved with the same amount of time?

THE COURT: Yes. Yes. You can assume that.

MS. BRAGMAN: Very good. Whatever the extension is, the other dates would move accordingly?

THE COURT: Yes. That's right. Okay.

MR. KOTTAHACHCHI: Your Honor, this is Nishan

Kottahachchi for the plaintiff. Generally what you said in

terms of the broad strokes the discovery is acceptable to the

plaintiffs. You know, we would ask that the mid-August update

is also fine with the plaintiffs, you know, given that the

discovery requests were served in October of 2009. We would

hope that the production would be made in another month. If

that's not possible, for technical reasons, of course we

understand. The one issue that was left outstanding here is

the interrogatory responses. Numbers 5, 6 and 11. That, we believe, could be answered well before mid-August. And we'd hope that would be done so.

THE COURT: Okay. Let me just --

MR. NOVACK: This is Mr. Novack again. We certainly don't expect to wait until mid-August to drop all of our discovery responses on the plaintiff. As soon as they're ready, we'll serve them.

THE COURT: Okay. That would be perfect. To the extent you have to --

MR. NOVACK: To do that with the documents.

THE COURT: And to the extent, Mr. Novack, that -for some reason you need to review documents before you get
your responses out, I just suggest you do the answers even if
it's on a rolling production basis. While it might not be the
most efficient it would hopefully keep the progress moving and
the plaintiff satisfied as well that they're getting this
information as you have it.

MR. NOVACK: Absolutely, Judge.

THE COURT: All right.

MR. NOVACK: We will following that instruction.

THE COURT: Okay. The last thing, and I don't know if it will come up for any of you, but if you do have a situation where you don't have certain material, and this is all you have, if you can just get a certification to that

extent as well then that often alleviates folks having to come to me. And I know the receiving party is often a little leery of getting a note or a letter that simply says this is all we have. And if you can just do a certification to that extent, it doesn't exist, we don't do this, it's not our practice or, you know, these are all the documents that we have relating to this then hand over the certification at the same time and hopefully you won't have to engage in a writing campaign then.

MR. NOVACK: Okay.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

THE COURT: Okay. So we're going to be a little bit fluid after -- my game plan is that after I get this August 20th submission that I can hopefully pretty quickly either get you folks on the phone if there's something to talk about, or simply enter a schedule extending the dates and I will plug in a telephone conference along the way. And generally I do that before fact discovery is set to close so I can make sure that we don't have any loose ends. So that's sort of the method to my madness. And if you folks have a suggestion for something different along the way, let me know. I know that these cases are often difficult to settle, but if sometime between now and when we're next scheduled to speak someone wants to raise the idea of coming in and sitting around the table with me, going to a mediator, I am open to any suggestions. And just because I'm not constantly raising it doesn't mean that I wouldn't entertain any suggestion that might get you to go away.

MR. MILLER: Your Honor, this is Greg Miller on behalf of plaintiff. Just one last question.

THE COURT: Sure.

MR. MILLER: Does the Court have a preference as to whether what we've discussed today should be memorialized in an order or is that something that the Court doesn't deem --

THE COURT: Well, I actually am on the record. And I sort of mentioned that at the beginning, so I sort of figured we have this as a record of --

MR. MILLER: Okay.

THE COURT: -- and then this way no one has to go through the process of memorializing it officially. So if you need a copy of this, you can certainly ask for the transcript or if you want to wait to see if we have any issues down the line we can always get it at that point. Good?

MR. MILLER: That sounds fine. Thank you.

THE COURT: Okay. All right, folks. Well, enjoy the rest of the summer. Hopefully I won't have to talk to you and that the production will go smoothly and I can just plug in a conference call for us in early fall. But if you need me, you know how to get me.

MR. MILLER: We appreciate it, Your Honor.

THE COURT: All right.

UNIDENTIFIED SPEAKER: Enjoy the summer.

THE COURT: Bye-bye.

<u>C E R T I F I C A T I O N</u>

I, GINA M. CERMAK, the assigned transcriber, do hereby certify that the foregoing transcript of the proceedings before the United States District Court, District of New Jersey, on July 14, 2010, 10:38 a.m. to 10:50 a.m., is prepared in full compliance with the current transcription format for Judicial Proceedings and is a true and accurate non-compressed transcript of the proceedings to the best of my knowledge and ability.

S/ Gina M. Cermak

November 15, 2010

GINA M. CERMAK

Date

AudioEdge Transcription, L.L.C.